DP
CRVS icon

Diadema Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Diadema Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.4M Buy
294,811
+50,000
+20% +$694K 0.56% 48
2026
Q1 		$3.58M Buy
+244,811
New +$3.91M 0.61% 43

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Diadema Partners's CRVS Position: Q2 2026 in Review

Diadema Partners increased its Corvus Pharmaceuticals (CRVS) stake by 20% in Q2 2026, buying an estimated $694K and bringing the position to 294,811 shares worth $4.4M. The position accounts for 0.56% of the portfolio, ranked #48.

Diadema Partners first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Diadema Partners held 294,811 shares of Corvus Pharmaceuticals worth $4.4M as of Q2 2026.
  • Diadema Partners bought 50,000 Corvus Pharmaceuticals shares in Q2 2026, an estimated $694K.
  • Corvus Pharmaceuticals made up 0.56% of Diadema Partners's portfolio in Q2 2026, its #48 holding.
  • Diadema Partners first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.